Fresh analysis suggests that individuals who discontinue new GLP-1 drugs like Mounjaro or Wegovy tend to recover lost weight at a significantly accelerated pace than those who halt conventional diet and exercise plans.
Findings released in a leading health publication shows that while obese individuals can lose a large proportion of their total mass while on the medication, the weight comes back at an estimated rate of 0.8 kg per month after stopping.
"Individuals purchasing these treatments must be informed of the potential of quick rebound weight gain when the treatment ends," stated expert Dr. Susan Jebb.
That rate of regain implies a reversion to pre-treatment mass within about 18 months.
Weighing Approaches
The analysis, which reviewed 37 of studies involving thousands of patients, contrasted the effects of these new drugs with other pills.
The team note that individuals who shed pounds through lifestyle changes alone generally experience a more gradual weight regain—around 0.1 kg a month—once they finish.
Explaining the Quick Regain
Experts believe the way of the drugs accounts for the heightened weight return.
These medications copy a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Artificially providing GLP-1 concentrations far above than normal could lead to the system to generate a reduced amount of its endogenous hormone, and may also lessen sensitivity to its actions," said Dr. Adam Collins, a dietetics expert.
"Discontinuation of this GLP-1 'fix' results in appetite is unsuppressed, making binge eating a significant risk."
A Lifelong Condition?
The NHS recommend the jabs for people with weight-linked health risks, alongside prescribed lifestyle changes.
Many experts say that, considering the likelihood of relapse, the therapy should be considered ongoing.
This perspective is supported by pharmaceutical companies, who note that the findings "emphasize the chronic character of obesity," similar to managing diseases like high blood pressure.
Patient Accounts
Individuals who have discontinued the medication explain a intense return of appetite.
"I experienced a trigger activating and you're instantly ravenous," described a patient.
This difficulty is compounded if individuals have not adopted sustainable lifestyle or habit modifications during treatment.
Growing Use
Figures indicate that millions of people in the UK have tried weight-loss jabs in the past year, with demand continuing to grow.
- Adoption is greater among women compared to men.
- The middle-aged age group shows the greatest level of interest.
- A large proportion obtain the medications through private healthcare rather than public health services.
Ultimately, experts caution that while GLP-1 drugs are powerful agents for weight loss, they are not a magic solution and long-term success relies on ongoing lifestyle management.
